Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolledPart A 16-week proof-of-concept data ...

Apogee begins patient dosing in Part B of phase 2 APEX trial of APG777 to treat moderate-to-severe atopic dermatitis: San Francisco Tuesday, February 4, 2025, 18:00 Hrs [IST] Apog ...

Patients benefiting from treatment will continue to APG777 maintenance dosing, which will evaluate 3- or 6-month dosing ... PD and efficacy against DUPIXENT in patients with moderate-to-severe ...

Apogee Therapeutics, Inc. has successfully completed enrollment ahead of schedule in Part A of its Phase 2 APEX clinical trial for its treatment APG777, which targets moderate-to-severe atopic ...

Patients benefiting from treatment will continue to APG777 maintenance dosing, which will evaluate 3- or 6-month dosing. Part B is a placebo-controlled dose optimization with approximately 280 ...

At the JPMorgan Conference last month, we detailed 10 ... patients are currently benefiting from Dupixent treatment. Three of these indications, atopic dermatitis, asthma, and nasal polyps have ...

Rinvoq is now capturing more than 20% in-place share in atopic dermatitis, as our communication ... Carbidopa. The six-month data from the Phase 3 studies show Tavapadon to be generally safe ...

That’s what we’ll be figuring out over the next months ... atopic-dermatitis-phase-3-trial-of-vtama-tapinarof-cream-1-in-adults-and-children-as-young-as-2-years-old/ 3. Fitch J. FDA approves ...

According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

Dupixent (dupilumab) was the first biologic treatment approved for atopic dermatitis. It became available in 2017. It is currently approved for adults, adolescents, and infants 6 months and older with ...